|
Consultation on Drug Discovery and Development
Gastrointestinal
Disorders: stomach emptying rate in rat, castor oil-induced diarrhea in rat, cholera toxin-induced enterectasis in mouse,
intestinal motility in mouse or rat, dextran sulfate sodium-induced inflammatory bowel disease in mouse or rat
General
Compound Characterization: conditioned taste aversion in rat, locomotor activity in mouse or rat, chronic locomotor activity
in high-value transgenic mouse (repeated measures design), conditioned avoidance retention in rat, acoustic startle response
in mouse or rat, electrical self-stimulation of brain in rat, modified Irwin, kappa opioid agonist-induced diuresis in rat,
8-OH-DPAT-induced flattened body posture and lip retraction in rat (5HT1a antagonism), DOI-induced head shakes in rat (5-HT2a
antagonism), potentiation of 5-HTP-induced wet dog shakes in rat (5-HT uptake inhibition), other drug interactions, blood
sample for pharmacokinetics in mouse or rat
Hypnotics and Pre-Anesthetics: sleeping time in rat
Muscle Spasm:
morphine-induced rigidity and Straub tail in mouse or rat
Obesity and Diabetes: reduction of body weight in genetically
obese mouse or rat, food consumption, insulin and glucose levels
Parkinson's Disease: haloperidol-induced catalepsy
in rat
|
